Straits Times Index
3,338.94 -9.93 (-0.30%) S&P 500
5,291.34 +7.94 (+0.15%) Dow
38,711.29 +140.26 (+0.36%) Nasdaq
16,857.05 +28.38 (+0.17%) Bitcoin USD
70,546.78 +1,514.78 (+2.19%) CMC Crypto 200
1,473.46 +26.31 (+1.82%)
REGN Nov 2024 1015.000 call
| Previous close | 59.76 |
| Open | 60.20 |
| Bid | 55.30 |
| Ask | 63.70 |
| Strike | 1,015.00 |
| Expiry date | 2024-11-15 |
| Day's range | 59.30 - 60.20 |
| Contract range | N/A |
| Volume | |
| Open interest | 5 |
ZacksHealth Care Stocks Show Relative Strength as S&P 500 Stalls
Several stocks are breaking out and trading near all-time highs.
Insider MonkeyIs Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) the Best Bet in Gene Therapy Industry?
We recently compiled a list of the 9 Best Gene Therapy Stocks to Buy Now and in this article, we discuss whether Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is the best bet in the gene therapy sector. Gene therapy involves treating illnesses by modifying, replacing, or supplementing faulty or missing genes responsible for a disease. This approach […]
BenzingaFDA Extends Review Deadline For Regeneron/Sanofi's Dupixent For 'Smoker's Lungs' Disease
On Friday, the FDA extended the target action date of priority review of supplemental application seeking approval for Dupixent (dupilumab) as an add-on maintenance treatment in certain adult patients with uncontrolled chronic obstructive pulmonary disease (COPD), a lung disease that’s usually caused by smoking. The revised target action date is September 27, 2024. The FDA accepted the application in February, with a target action date of June 27, 2024. The FDA did not raise any concerns regardi
